



Immunization, Vaccines and Biologicals

SAGE meeting of 8 - 10 April 2008

Declaration of Interests

All members completed a declaration of interest. Only two members reported any interest.

Dr Georges Peter

Dr Peter reported serving on the meningococcal Advisory Board for GlaxoSmithKline for which he receives a limited amount of consultancy fees. The last meeting was in 2006. He serves on two Safety Monitoring Board for trials involving RotaTeqTM and one investigational H5N1 vaccine and for which he receives a small financial compensation from Merck & Co Inc. and Novavax respectively. In view of the topics discussed at the meeting, it was agreed with the SAGE Chairperson that Dr. Peter would not take part of any decision making process in relation with the "Investment case for elimination of meningococcal meningitis as a public health problem in Africa" although he could contribute to the discussion. This session was intended solely for information and for discussion.

Dr Helen Rees

Dr Rees reported that the institution where she works i.e. the Reproductive Health & HIV Research Unit of the University of the Witwatersrand is receiving a small grant from Merck & Co Inc. The purpose of the grant is to coordinate a Human papillomavirus vaccine trial among young men. The role of the Reproductive Health & HIV Research Unit, is to provide good clinical practice monitoring of three private general practitioners. She has no personal involvement in negotiating or implementing the grant.

Last updated: 23 April 2010